View in EDS

A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.

Saved in:
Bibliographic Details
Title: A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
Authors: Malhotra J; Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey. Electronic address: jm1940@cinj.rutgers.edu., Nikolinakos P; Hematology and Medical Oncology, University Cancer & Blood Center, Athens, Georgia., Leal T; Hematology-Oncology, Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin., Lehman J; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Morgensztern D; Division of Oncology, Washington University School of Medicine, St. Louis, Missouri., Patel JD; Department of Medicine (Oncology), Feinberg School of Medicine, Northwestern University, Chicago, Illinois., Wrangle JM; Department of Medicine, Medical University of South Carolina, Charleston, South Carolina., Curigliano G; Division of Early Drug Development for Innovative Therapy, Istituto Europeo di Oncologia, IRCCS, Milano, Italy; Department of Oncology and Haematology, University of Milano, Milano, Italy., Greillier L; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille, Hôpital de la Timone, Aix Marseille University, Marseille, France., Johnson ML; Tennessee Oncology, Sarah Cannon Research Institute, Nashville, Tennessee., Ready N; Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina., Robinet G; Service de Pneumologie, CHU de Brest-Hôpital Morvan, Brest, France., Lally S; AbbVie Stemcentrx, South San Francisco, California., Maag D; AbbVie Inc., Chicago, Illinois., Valenzuela R; AbbVie Stemcentrx, South San Francisco, California., Blot V; AbbVie Inc., Chicago, Illinois., Besse B; Gustave Roussy, Villejuif, France; Espace Technologique, Paris-Saclay University, Saint-Aubin, France.
Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2021 Sep; Vol. 16 (9), pp. 1559-1569. Date of Electronic Publication: 2021 Feb 27.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33652156
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Malhotra+J%22">Malhotra J</searchLink>; Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey. Electronic address: jm1940@cinj.rutgers.edu.<br /><searchLink fieldCode="AU" term="%22Nikolinakos+P%22">Nikolinakos P</searchLink>; Hematology and Medical Oncology, University Cancer & Blood Center, Athens, Georgia.<br /><searchLink fieldCode="AU" term="%22Leal+T%22">Leal T</searchLink>; Hematology-Oncology, Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin.<br /><searchLink fieldCode="AU" term="%22Lehman+J%22">Lehman J</searchLink>; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Morgensztern+D%22">Morgensztern D</searchLink>; Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.<br /><searchLink fieldCode="AU" term="%22Patel+JD%22">Patel JD</searchLink>; Department of Medicine (Oncology), Feinberg School of Medicine, Northwestern University, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Wrangle+JM%22">Wrangle JM</searchLink>; Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.<br /><searchLink fieldCode="AU" term="%22Curigliano+G%22">Curigliano G</searchLink>; Division of Early Drug Development for Innovative Therapy, Istituto Europeo di Oncologia, IRCCS, Milano, Italy; Department of Oncology and Haematology, University of Milano, Milano, Italy.<br /><searchLink fieldCode="AU" term="%22Greillier+L%22">Greillier L</searchLink>; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille, Hôpital de la Timone, Aix Marseille University, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Johnson+ML%22">Johnson ML</searchLink>; Tennessee Oncology, Sarah Cannon Research Institute, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Ready+N%22">Ready N</searchLink>; Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina.<br /><searchLink fieldCode="AU" term="%22Robinet+G%22">Robinet G</searchLink>; Service de Pneumologie, CHU de Brest-Hôpital Morvan, Brest, France.<br /><searchLink fieldCode="AU" term="%22Lally+S%22">Lally S</searchLink>; AbbVie Stemcentrx, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Maag+D%22">Maag D</searchLink>; AbbVie Inc., Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Valenzuela+R%22">Valenzuela R</searchLink>; AbbVie Stemcentrx, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Blot+V%22">Blot V</searchLink>; AbbVie Inc., Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Besse+B%22">Besse B</searchLink>; Gustave Roussy, Villejuif, France; Espace Technologique, Paris-Saclay University, Saint-Aubin, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101274235%22">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</searchLink> [J Thorac Oncol] 2021 Sep; Vol. 16 (9), pp. 1559-1569. <i>Date of Electronic Publication: </i>2021 Feb 27.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101274235 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1556-1380 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215560864%22">15560864 </searchLink><i>NLM ISO Abbreviation: </i>J Thorac Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33652156
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jtho.2021.02.022
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1559
    Titles:
      – TitleFull: A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Malhotra J
      – PersonEntity:
          Name:
            NameFull: Nikolinakos P
      – PersonEntity:
          Name:
            NameFull: Leal T
      – PersonEntity:
          Name:
            NameFull: Lehman J
      – PersonEntity:
          Name:
            NameFull: Morgensztern D
      – PersonEntity:
          Name:
            NameFull: Patel JD
      – PersonEntity:
          Name:
            NameFull: Wrangle JM
      – PersonEntity:
          Name:
            NameFull: Curigliano G
      – PersonEntity:
          Name:
            NameFull: Greillier L
      – PersonEntity:
          Name:
            NameFull: Johnson ML
      – PersonEntity:
          Name:
            NameFull: Ready N
      – PersonEntity:
          Name:
            NameFull: Robinet G
      – PersonEntity:
          Name:
            NameFull: Lally S
      – PersonEntity:
          Name:
            NameFull: Maag D
      – PersonEntity:
          Name:
            NameFull: Valenzuela R
      – PersonEntity:
          Name:
            NameFull: Blot V
      – PersonEntity:
          Name:
            NameFull: Besse B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2021 Sep
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1556-1380
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
              Type: main
ResultId 1